An analysis of over 17,000 oncology drug development trajectories revealed that trials incorporating biomarkers had almost twice the overall success probability (10%) compared to those without (5%). This success boost is most significant in early-phase (Phase 1 and 2) trials.

The extensive translational and biomarker work published in Nature from a Phase 1 study of Casdatifan is a model for modern drug development. Understanding the drug's mechanism, pharmacodynamics, and response signatures from day one provides a 'backup plan' and helps avoid costly Phase 3 failures.

Recent failures in trials for hsCRP and Lp(a) targets highlight a growing challenge in cardiovascular R&D. Existing treatments like statins and GLP-1s have raised the standard of care so high that proving an incremental benefit for a new drug is incredibly difficult, requiring massive, expensive, and often unsuccessful studies.

Contrary to expectations that major trial failures would deter investment, large pharmaceutical companies are accelerating efforts in atherosclerotic cardiovascular disease. They are initiating new Phase 2 trials with novel mechanisms like NLRP3 inhibitors, signaling a strong underlying belief in the pathway and a continued strategic commitment to the indication.

Two major cardiovascular trials targeting novel biomarkers (LPA and hs-CRP) failed to improve outcomes despite successfully lowering the biomarkers. This has dampened enthusiasm for novel targets and shifted R&D and investor focus back to established, "unsexy" pathways like PCSK9, GLP-1, and SGLT2, which are now viewed as less risky.

Many promising biomarkers are merely correlated with a disease, not a cause. Developing effective drugs requires targeting mechanisms with a direct causal effect on the outcome. This distinction is so critical that Valo Health has a "Chief Causal AI Officer" role to emphasize the focus.

Alt-Pep's SOBA blood test is a crucial companion diagnostic for its SOBIN-AD therapeutic. It allows for patient stratification by confirming the presence of the drug's target—toxic oligomers. This creates a rare, direct link between biomarker, target, and mechanism, significantly increasing the probability of clinical success.

Biomarkers provide value beyond predicting patient response. Their core function is to answer 'why' a treatment succeeded or failed. This explanatory power informs sequential therapy decisions and provides crucial scientific insights that advance the entire medical field, not just the individual patient's case.

Unlike big pharma, capital-constrained biotechs can't afford long, expensive trials. MindImmune’s CEO advocates for designing clever Phase 1b studies that use biomarker endpoints to get an early efficacy signal in months, not years, thereby de-risking the program for investors much faster.